. Author manuscript; available in PMC: 2022 Jul 1.

Published in final edited form as: J Allergy Clin Immunol Pract. 2021 Mar 27;9(7):2761–2769.e2. doi: 10.1016/j.jaip.2021.02.053

Table 3.

Asthma outcomes after intramuscular triamcinolone administration, by baseline eosinophil cationic protein (ECP) tertile. Data represent the mean ± standard error of the mean.

	Low ECP (<3.12 ng/ml)	Intermediate ECP (3.12–16.22 ng/mL)	High ECP (≥16.23 ng/mL)

ACQ-6 score	0.55 ± 0.12	0.95 ± 0.22	0.96 ± 0.14^*
Mean difference from baseline¹	0.16 ± 0.14	0.29 ± 0.16	0.36 ± 0.14^*

PAQLQ score	6.24 ± 0.14	5.77 ± 0.22	5.79 ± 0.16
Mean difference from baseline	−0.60 ± 0.16	−0.48 ± 0.18	−0.48 ± 0.12

FEV₁ (% predicted)	100.1 ± 2.7	93.6 ± 3.5	88.4 ± 2.9^*
Mean difference from baseline	−0.97 ± 1.78	0.61 ± 2.92	−2.66 ± 2.46

FEV₁/FVC (% predicted)	93.9 ± 1.6	89.7 ± 2.4	87.4 ± 1.8^*
Mean difference from baseline	0.79 ± 1.63	0.25 ± 1.72	2.10 ± 1.41

Pre-triamcinolone value minus post-triamcinolone value

p<0.05 vs. Low ECP